Benzinga
Benzinga
Benzinga
domenica, settembre 27

Kymera Therapeutics Inc

KYMRNASDAQ
Trade with Public
Trade with Public
$111.95
-3.86-3.33%
In chiusura: Sep 25, 5:00 PM EST
$111.95
N/A
Post-mercato: Sep 25, 4:00 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

Kymera Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Kymera Therapeutics (KYMR).

Price Target Range — 12 Quarters

Analyst Consensus — 24 Analysts

21Buy
3Hold
Consensus RatingBuy# Analysts24Avg. Consensus PT$113Upside to Avg. PT+1.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →
DateFirmAnalystActionRating ChangePrice Target
Sep 22, 2026StifelAlex ThompsonPT RaiseBuy$132→$152
Sep 14, 2026B of A SecuritiesTazeen AhmadPT RaiseBuy$123→$144
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.
Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Kymera Therapeutics, Raises Price Target to $144

B of A Securities analyst Tazeen Ahmad maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $123 to $144.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades Kymera Therapeutics to Outperform

Wolfe Research analyst Andy Chen upgrades Kymera Therapeutics (NASDAQ:KYMR) from Peer Perform to Outperform.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Kymera Therapeutics, Raises Price Target to $170

Guggenheim analyst Brad Canino maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $135 to $170.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on Kymera Therapeutics, Raises Price Target to $151

Wells Fargo analyst Derek Archila maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $116 to $151.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Kymera Therapeutics, Raises Price Target to $139

Barclays analyst Eliana Merle maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $133 to $139.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved